Antimicrobial resistant pathogens are one of the biggest global health threats faced by society. A growing list of infections are becoming harder, and sometimes impossible, to treat as antibiotics become less and less effective. Drug-resistant diseases already kill around 700,000 people each year, and it is estimated that this could swell to 10 million by 2050 if no action is taken. That is even more than the number of people that die from cancer every year worldwide.


New antimicrobial compounds, primarily antibiotics to date, are kept tightly regulated as “last-line” choices only for multi-drug resistant infections. This means that companies cannot make a profit or even securely make back their investment with novel antimicrobials. This field is widely regarded as suffering from a “broken” business model. Therefore there is only little innovation in antimicrobial compounds.


AMResolute develops multiple antimicrobial compounds in parallel, tapping into NLC’s extensive network of inventors to bring new, innovative assets into the company. This allows AMResolute to de-risk individual assets and pool the resources needed for all projects. 

Currently AMResolute develops unrelated compounds against three different bacterial pathogens, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Staphylococcus aureus, all of which are on the WHO’s list of “bacteria for which new antibiotics are urgently needed”.


All three antimicrobial compounds are currently in hit-to-lead stage preclinical development. It is expected is that the first compound could be ready for market introduction by 2029 – 2030.

This venture will be part of the NLC Foundation, a non-profit entity that helps fund projects in areas of high medical and societal need.

Meet the team


Evert Küppers


Pharmaceutical executive with over 18 years of successful practice in different, international work settings (large pharma, biotech start-up, pharma management consultancy) performing hands-on corporate tasks (Operations, BusDev./licensing, fundraising, org).


Johanneke Maenhout

Venture Partner

Pro-active, dedicated and an analytically strong teamplayer, with a decade of experience in strategic and operational health care consulting and health economics. Interested in accelerating the role of technology and innovation in improving health and the health care landscape. At NLC, she carries main responsibility for a smooth venture building process and personal development of the people within.